Atara Biotherapeutics, Inc (ATRA) Dividend History

Company News

• Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

  Wolf Haldenstein Adler Freeman & Herz LLP is investigating Atara Biotherapeutics, Inc. for potential securities law violations after the company received a Complete Response Letter from the FDA regarding its Ebvallo drug, leading to a clinical hold and workforce reduction.

  GlobeNewswire Inc.
• FUJIFILM Diosynth Biotechnologies Celebrates the Expansion Completion at its California Cell Therapy Facility

  FUJIFILM Diosynth Biotechnologies has completed the expansion of its cell therapy manufacturing facility in Thousand Oaks, California, adding two new production suites and increasing cleanroom capacity to support the growing demand for cell therapies.

  GlobeNewswire Inc.
• Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire

  The 73rd Emerging Growth Conference is scheduled for July 17-18, 2024, featuring presentations from various companies in the healthcare, technology, and energy sectors.

  GlobeNewswire Inc.

  Featured Companies: ASPI AYTU CLNN CVKD GDTC IQST LGMK XXII
• Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

  Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.

  Zacks Investment Research

  Featured Companies: BIIB
• GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals

  GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule

  Zacks Investment Research

  Featured Companies: ENTX